Eugia Pharma Specialities Limited – FDA Warning Letter, Feb 27, 2026

On August 13, 2026, the FDA issued a warning letter to Eugia Pharma Specialities Limited following an inspection of its Kolthur Village facility from February 16 to 27, 2026. The agency identified significant violations of Current Good Manufacturing Practice (CGMP) regulations, which are the federal standards for ensuring drug quality and safety. Consequently, the firm"s sterile injectable products are considered adulterated under the Federal Food, Drug, and Cosmetic Act.

The main violations centered on inadequate facility design and poor operational controls. Inspectors found that the processing lines lacked sufficient physical barriers to prevent contamination, leading to frequent manual interventions by staff in sterile areas. Furthermore, the company failed to properly monitor the environment for microbes and exhibited poor aseptic techniques, such as operators touching sterile components or leaning over open production lines. The FDA also noted that the company’s process simulations—used to ensure manufacturing sterility—failed to include several critical production steps.

Because similar issues were discovered at other Eugia facilities, the FDA expressed concern regarding systemic management failures. The company is required to perform a comprehensive, independent risk assessment of its manufacturing hazards and submit a detailed remediation plan. This plan must involve redesigning equipment, improving staff training, and increasing quality oversight. Failure to address these violations promptly may result in the FDA withholding product approvals or blocking the company"s drugs from entering the United States.